People In Brief: NSF, Xango, GNC, NCCAM, MHRA

FDA’s Williams moves to NSF; Xango founders take international posts; Fortino returns to GNC as VP; Hamilton moves up at Hyland’s; Shurtleff moves to NCCAM; more People In Brief.

Bradford Williams, a former manager in FDA’s good manufacturing practices program for dietary supplements, starts as technical manager of NSF International’s Supplement GMP Facility Registration Program. Williams worked at FDA for more than 30 years, including eight in the agency’s Division of Dietary Supplement Programs, where he assisted in developing supplement GMP requirements and training programs for FDA investigators and managed the review of more than 350 facility investigations and enforcement actions. “Since Brad has worked with the FDA’s GMP program since its inception, his expertise will assist NSF in continuing to align its GMP program with FDA regulations,” said Ed Wyszumiala, general manager of Ann Arbor, Mich.-based NSF’s supplement programs, in a July 22 release.

Multilevel dietary supplement marketer Xango LLC on July 3 appoints two company founders to new roles: Joe Morton as president...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By 

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla

 

Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

 

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.

More from Geography

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By 

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.